{'fraction_non_alphanumeric': 0.02226027397260274, 'fraction_numerical': 0.0136986301369863, 'mean_word_length': 5.290322580645161, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The CRASH-2 trial of an antifibrinolytic agent in traumatic haemorrhage: an international collaboration.

The CRASH-2 trial is a World Health Organization (WHO) supported large international multi-centre randomized placebo controlled trial of the effects of the antifibrinolytic agent tranexamic acid on death and transfusion requirements in adult trauma patients with significant haemorrhage. The trial aims to recruit 20,000 patients worldwide. This article gives the rationale for the trial, an update on its progress and is an invitation to doctors in India to join CRASH-2 trial.